<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>ALKEM</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">ALKEM</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="alkem-laboratories-limited" class="section level1">
<h1>Alkem Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.ALKEM.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-11-27 </em></p>
<div id="alkem-laboratories-ltd.-alkem-analysis-headwinds-tailwinds-growth-prospects-and-key-risks" class="section level9">
<p class="heading">Alkem Laboratories Ltd. (ALKEM) Analysis: Headwinds, Tailwinds, Growth Prospects, and Key Risks</p>
<p>Alkem Laboratories Ltd., a leading Indian pharmaceutical company (5th largest by IPM value, #3 in prescriptions), reported robust Q2 &amp; H1 FY26 results amid positive operational updates. Key highlights include 17.2% YoY revenue growth to ₹40,010 Mn (consolidated), EBITDA margin expansion to 23.0% (+100 bps YoY), and domestic leadership in the Acute segment. International sales surged 29.5% YoY, driven by US (28%) and non-US (32.4%) growth. Below is a structured analysis based on the provided disclosures.</p>
<div id="tailwinds-positive-catalysts" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Catalysts)</strong></p>
<ul>
<li><strong>Strong Financial Momentum</strong>: Q2 FY26 revenue +17.2% YoY (H1 +14.4%), EBITDA +22.3% YoY (margin 23%), PAT +11.1% YoY (19.1% margin). Gross margins stable at ~65%. Net cash position of ₹49.4 Bn as of Sep 30, 2025. ROCE at 28.1% (FY25).</li>
<li><strong>Domestic Market Leadership</strong>: #1 in Acute IPM (IQVIA SSA), in-line with IPM growth (6.4% YoY). Outperformed in 6 key therapies (e.g., Anti-infectives 1.2x IPM, GI 3.1x). 18 brands &gt;₹1 Bn, PAN franchise &gt;₹10 Bn. Domestic contribution ~70%.</li>
<li><strong>International Expansion</strong>: US sales ₹7,649 Mn (+28% YoY, 19.3% of total); filed 187 ANDAs (163 approvals). Non-US +32.4% (Australia/Europe). 4 new US launches in Q2.</li>
<li><strong>Regulatory Cleanliness</strong>: No critical/major GMP observations (Armenia inspection). USFDA EIRs/no observations at multiple facilities (Baddi, Daman, Ankleshwar, etc.). Recent virtual USFDA inspection at Daman.</li>
<li><strong>Innovation &amp; Pipeline</strong>: R&amp;D spend 3.3% of sales (down from 4.3%, efficient). Launches: DSS probiotic (exclusive high-CFU strengths, gut health market ~₹2,071 Cr, 14% CAGR). CSR-funded IIT Bombay research center for immuno-therapeutics/regenerative medicines (20-25% of 7-year CSR spend).</li>
<li><strong>Balance Sheet Strength</strong>: Equity ₹138 Bn, low debt (borrowings ~₹20 Bn), healthy liquidity (cash equivalents + deposits).</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Regulatory/Compliance Noise</strong>: GST demand of ₹1.81 Cr (Gujarat GSTIN, FY18-25, ineligible ITC allegation; received Nov 17, 2025). Smaller penalty ₹2.16 lakh (UP, Oct 31, 2025, document discrepancies). Company contests both; no material impact stated, but appeals ongoing.</li>
<li><strong>Margin Pressures</strong>: PAT growth (11.1%) lagged revenue due to higher employee costs (+16% YoY) and other expenses. R&amp;D normalization post-hike.</li>
<li><strong>Domestic Moderation</strong>: Growth (12.4%) in-line with IPM; chronic therapies still nascent (e.g., Anti-diabetic 2.2% share).</li>
<li><strong>Macro Factors</strong>: GST revision adapted seamlessly, but forex volatility (international ~30% revenue) and input costs could pressure margins.</li>
</ul>
</div>
<div id="growth-prospects" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>High Double-Digit Outlook</strong>: Domestic: Leverage #1 Acute position, 12,500+ field force, 35 top-300 IPM brands. Target chronic expansion (diabetes, neuro). International: US pipeline (24 pending approvals), CDMO/Sacubitril-Valsartan traction; non-US via Australia/Europe/LatAm. FY25 revenue ₹1.3 Lakh Cr base.</li>
<li><strong>Product Innovation</strong>: DSS launch taps growing probiotics market. Biosimilars (Enzene), Medtech entry (Adroit/Bombay Ortho acquisitions).</li>
<li><strong>R&amp;D/Partnerships</strong>: 163 US ANDAs, IIT Bombay center for high-precision therapies. Facility expansions (18 plants).</li>
<li><strong>Market Tailwinds</strong>: IPM growth, US generics opportunity, global presence (US &gt;$200 Mn FY18 milestone crossed). MSCI India inclusion, shareholding stable (promoters 51%).</li>
<li><strong>Valuation Upside</strong>: MCap ₹6.5 Lakh Cr (Sep 30, 2025, price ₹5,425). EPS ₹119.5 (H1 FY26, +15.8% YoY).</li>
</ul>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26</th>
<th>YoY Growth</th>
<th>H1 FY26</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue</td>
<td>₹40,010 Mn</td>
<td>+17.2%</td>
<td>₹73,721 Mn</td>
<td>+14.4%</td>
</tr>
<tr class="even">
<td>EBITDA Margin</td>
<td>23.0%</td>
<td>+100 bps</td>
<td>22.5%</td>
<td>+140 bps</td>
</tr>
<tr class="odd">
<td>PAT (post-MI)</td>
<td>₹7,651 Mn</td>
<td>+11.1%</td>
<td>₹14,293 Mn</td>
<td>+15.8%</td>
</tr>
</tbody>
</table>
</div>
<div id="key-risks" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="41%" />
<col width="25%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>GST demands (₹1.81 Cr + small); USFDA inspections (e.g., Daman virtual).</td>
<td>Appeals filed; clean track record (EIRs/no obs.).</td>
</tr>
<tr class="even">
<td><strong>Execution/Competition</strong></td>
<td>International ramp-up (US filings, launches); domestic IPM competition.</td>
<td>Strong pipeline (187 ANDAs), leadership in Acute/GI.</td>
</tr>
<tr class="odd">
<td><strong>Financial</strong></td>
<td>Forex (30% intl. revenue), input inflation, working capital (trade receivables up).</td>
<td>Net cash ₹49 Bn; operating cash ₹5.4 Bn (H1).</td>
</tr>
<tr class="even">
<td><strong>Operational</strong></td>
<td>Supply chain (inventories ₹30 Bn), R&amp;D efficacy.</td>
<td>18 facilities, diversified geographies.</td>
</tr>
<tr class="odd">
<td><strong>Macro</strong></td>
<td>Rupee volatility, policy changes (GST).</td>
<td>Hedging, domestic focus (70%).</td>
</tr>
<tr class="even">
<td><strong>Litigation</strong></td>
<td>Ongoing GST appeals; potential escalations.</td>
<td>“No material impact” per disclosures.</td>
</tr>
</tbody>
</table>
</div>
<div id="summary" class="section level12">
<p class="heading"><strong>Summary</strong></p>
<p><strong>Bullish Outlook with Muted Near-Term Noise</strong>: Tailwinds dominate – stellar Q2/H1 growth, domestic #1 Acute rank, US/non-US surge, clean regs, and innovation (DSS, IIT collab) position Alkem for 15-20%+ revenue CAGR. Headwinds are minor (GST ~0.1% of quarterly revenue, contested). Growth anchored in India (70% revenue) + intl. leverage; risks regulatory/executional but mitigated by balance sheet (net cash) and track record. Stock likely supported at current levels (MCap ₹6.5 Lakh Cr); monitor GST appeals and Q3 results for confirmation. Positive for long-term investors in pharma generics/biosimilars.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
